| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163246446P | 2021-09-21 | 2021-09-21 | |
| US202263310884P | 2022-02-16 | 2022-02-16 |
| Publication Number | Publication Date |
|---|---|
| CL2024000822A1true CL2024000822A1 (en) | 2024-07-26 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000822ACL2024000822A1 (en) | 2021-09-21 | 2024-03-20 | Antipsychotic prolonged-release injectable composition |
| Country | Link |
|---|---|
| EP (1) | EP4404913A1 (en) |
| JP (1) | JP2024534540A (en) |
| KR (1) | KR20240056731A (en) |
| CN (1) | CN117979957A (en) |
| AR (1) | AR127101A1 (en) |
| AU (1) | AU2022351480A1 (en) |
| CA (1) | CA3230338A1 (en) |
| CL (1) | CL2024000822A1 (en) |
| CO (1) | CO2024005012A2 (en) |
| IL (1) | IL311632A (en) |
| MX (1) | MX2024003381A (en) |
| PE (1) | PE20240934A1 (en) |
| TW (1) | TW202313047A (en) |
| WO (1) | WO2023046731A1 (en) |
| ZA (1) | ZA202402860B (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230372331A1 (en)* | 2022-05-18 | 2023-11-23 | Anxo Pharmaceutical Co., Ltd. | Pharmaceutical composition |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5656297A (en) | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
| JP3645906B2 (en) | 1993-11-19 | 2005-05-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| IL130532A0 (en) | 1996-12-20 | 2000-06-01 | Alza Corp | Gel composition and methods |
| US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
| US6194006B1 (en) | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| ES2283394T3 (en) | 2000-01-11 | 2007-11-01 | Bertex Pharma Gmbh | IMPLEMENTATION KIT CONTAINING A SUPPORT PHASE AND A SOLVENT. |
| AU2002226000A1 (en) | 2000-11-13 | 2002-05-21 | Atrix Laboratories, Inc. | Injectable sustained release delivery system with loperamide |
| CA2494400A1 (en) | 2002-07-31 | 2004-02-05 | Alza Corporation | Injectable multimodal polymer depot compositions and uses thereof |
| WO2004081196A2 (en) | 2003-03-11 | 2004-09-23 | Qlt Usa Inc. | Formulations for cell- schedule dependent anticancer agents |
| EP1615923A1 (en) | 2003-04-22 | 2006-01-18 | Synthon B.V. | Risperidone monohydrochloride |
| US8221778B2 (en) | 2005-01-12 | 2012-07-17 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| CA2553254C (en) | 2004-01-12 | 2013-12-17 | The Trustees Of The University Of Pennsylvania | Long-term delivery formulations and methods of use thereof |
| US8313763B2 (en) | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| MX2009003735A (en) | 2006-10-05 | 2009-04-22 | Panacea Biotec Ltd | Injectable depot composition and its' process of preparation. |
| FR2908775B1 (en) | 2006-11-17 | 2012-08-31 | Biomatlante | HYDROGEL AND ITS BIOMEDICAL APPLICATIONS |
| DK2167039T3 (en) | 2007-05-18 | 2017-01-09 | Durect Corp | Improved depot formulations |
| MX354603B (en) | 2007-05-25 | 2018-03-13 | Indivior Uk Ltd | Sustained delivery formulations of risperidone compounds. |
| US8629172B2 (en) | 2008-04-18 | 2014-01-14 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising clonidine |
| ES2600797T3 (en) | 2008-08-12 | 2017-02-10 | Novartis Ag | Pharmaceutical compositions |
| WO2011042453A1 (en) | 2009-10-06 | 2011-04-14 | Ascendis Pharma As | Subcutaneous paliperidone composition |
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
| US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
| PT2394663T (en) | 2010-05-31 | 2021-11-26 | Farm Rovi Lab Sa | Compositions for injectable in-situ biodegradable implants |
| ES2589106T3 (en) | 2010-05-31 | 2016-11-10 | Laboratorios Farmaceuticos Rovi, S.A. | Injection controlled antipsychotic composition |
| PL2529757T3 (en) | 2011-05-31 | 2014-04-30 | Farm Rovi Lab Sa | Paliperidone implant formulation |
| DK2529756T3 (en) | 2011-05-31 | 2021-08-02 | Farm Rovi Lab Sa | Risperidone and / or paliperidone implant formulation |
| Publication number | Publication date |
|---|---|
| MX2024003381A (en) | 2024-04-19 |
| CA3230338A1 (en) | 2023-03-30 |
| EP4404913A1 (en) | 2024-07-31 |
| AU2022351480A1 (en) | 2024-03-28 |
| AR127101A1 (en) | 2023-12-20 |
| ZA202402860B (en) | 2024-11-27 |
| CN117979957A (en) | 2024-05-03 |
| WO2023046731A1 (en) | 2023-03-30 |
| IL311632A (en) | 2024-05-01 |
| TW202313047A (en) | 2023-04-01 |
| JP2024534540A (en) | 2024-09-20 |
| CO2024005012A2 (en) | 2024-08-08 |
| PE20240934A1 (en) | 2024-04-30 |
| KR20240056731A (en) | 2024-04-30 |
| Publication | Publication Date | Title |
|---|---|---|
| CO2024005012A2 (en) | Antipsychotic prolonged-release injectable composition | |
| CL2016001590A1 (en) | Hot melt adhesive | |
| NZ601140A (en) | Retractable syringe with improved delivery efficiency and locking system | |
| RU2476246C2 (en) | New safe self-block, self-destructing syringe | |
| CL2012003605A1 (en) | A self-destructive insulin syringe that has a cylinder, a plunger rod with a cone-shaped cap, a hollow plunger with a surface with an open surface at the bottom and hollow at the top, and a stop to deform when pressed against the bottom surface of the plunger after finishing the injection. | |
| AR024228A1 (en) | A PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INSULIN SENSITIZER AND ANOTHER ANTI-DIABETIC AGENT | |
| AR056554A1 (en) | FORMULATION OF PHARMACO OF SMALL SUSTAINED RELEASE MOLECULA | |
| CL2009000541A1 (en) | Use of an activatable matrix degrading enzyme (amde) for the formulation of a drug for sub-epidermal administration; pharmacological composition and its use; combination comprising amde, an activator and an agent; container for amde and activator; kit comprising said container | |
| ES2530626T3 (en) | Benzoxazine resins | |
| BR112016001544A8 (en) | pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an anti-inflammatory agent | |
| MX387891B (en) | INJECTABLE PREPARATION COMPRISING A GEL COMPOSITION OF ARIPIPRAZOLE AND POLYNYLPYRROLIDONE AS A SUSPENDING AGENT AND THE USE THEREOF FOR TREATING SCHIZOPHRENIA, BIPOLAR DISORDER OR DEPRESSION | |
| PE20160102A1 (en) | HIGH DENSITY POLYETHYLENE (HDPE) MULTIMODAL | |
| AR059395A1 (en) | BROOKFIELDTM WATER RETENTION AND VISCOSITY STUCK SAUCE MANUFACTURING PROCESS IMPROVED USING A PEINE POLYMER WITH AT LEAST A POLYKYLENE OXIDE LINKED FUNCTION | |
| PA8815501A1 (en) | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF THYROSINE QUINASE INHIBITOR | |
| AR130840A2 (en) | A SYSTEM WITH PLATFORM FOR MOUNTING A DRUG DELIVERY DEVICE | |
| MX389348B (en) | SYRINGE WITH DISABLING MECHANISM. | |
| CL2018001641A1 (en) | Polyethylene formulations with improved barrier and hardness for molding applications. | |
| BR112015028040A2 (en) | acrylate-derived main chain-containing polymer, methods for preparing polymers, pharmaceutical formulations and methods for increasing the solubility of a drug | |
| MX374431B (en) | FRANGIBLE PUSH DISC FEATURE TO PREVENT REUSE | |
| MX2021011061A (en) | Stable basic electrolyte material and solvent material containing same. | |
| MX2023013840A (en) | PIPERAZINE DERIVATIVE AND USE OF THE SAME IN MEDICINE. | |
| BR112016028635A2 (en) | absorbent article with tack-free adhesive | |
| MX2017012636A (en) | Crane having effectively coincident gantry and boom forces upon an upperstructure. | |
| AR103018A1 (en) | POLYETHYLENE POLYMER COMPOSITIONS WITH LOW TURBIDITY | |
| MX2019004830A (en) | PHARMACEUTICAL COMPOSITIONS AND USES OF THEM. |